NCT03374852 2025-04-29
CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer
Thomas Jefferson University
Phase 2 Withdrawn
Clinical Trials
5 trialsNCT05854966 2024-09-19
CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Wake Forest University Health Sciences
Phase 2 Withdrawn
NCT06518538 2024-08-15
Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer
Cornerstone Pharmaceuticals
Phase 2 Withdrawn
NCT01520805 2016-12-29
Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome
Cornerstone Pharmaceuticals
Phase 2 Withdrawn
NCT01830322 2013-08-14
Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer
Cornerstone Pharmaceuticals
Phase 2 Withdrawn